IMMA Health

Based in Israel, IMMA Health innovates in fertility management with its at-home ovarian stimulation monitoring system designed for In Vitro Fertilization (IVF), enhancing user experience and convenience for fertility treatments. IMMA Health, founded in 2021, is located in Modi'in-Maccabim-Re'ut, Israel. The company specializes in fertility solutions through its innovative home monitoring system. It has completed 2 deals to date, with the most recent deal occurring on September 15, 2025, when it raised USD 2.

5 mn in a SEED funding round led by iXcore, bringing the total amount raised to USD 2. 5 mn. Imma focuses on revolutionizing the fertility journey through its innovative at-home ovarian stimulation monitoring system designed for In Vitro Fertilization (IVF). This device allows individuals to conveniently monitor their fertility status in the comfort of their own homes, thereby alleviating stress and minimizing disruption to their daily routines.

By providing a user-friendly interface for home ultrasound monitoring, Imma aims to enhance the overall experience for those undergoing fertility treatments. The target clientele includes individuals and couples seeking fertility solutions, healthcare providers, and fertility clinics, with the product functioning across diverse geographical markets, particularly in North America and Europe. The technology has been developed to cater to the specific needs of patients, offering a sense of comfort while addressing the prevalence of anxiety associated with traditional monitoring methods. Imma's revenue generation strategy is primarily centered around direct-to-consumer sales and potential partnerships with healthcare institutions.

The company’s flagship product, the at-home ultrasound device, is expected to be offered through a subscription model, enabling users to access ongoing support and monitoring services. This model not only provides a steady revenue stream but also ensures that clients have continuous access to the latest technological advancements and guidance. Revenue is further bolstered by collaborations with employers and insurers who recognize the financial benefits of facilitating convenient home monitoring solutions for employees, ultimately leading to cost savings associated with productivity losses. Specific pricing structures and transaction details are tailored to align with the needs of both individual consumers and healthcare partners, ensuring a comprehensive approach to service delivery in the fertility care landscape.

In September 2025, IMMA Health raised USD 2. 5 mn in Seed funding, part of a larger USD 4. 8 mn seed funding round, led by new investor iXcore. This funding will be utilized to accelerate product development, support clinical trials, and expand market presence across Europe and North America.

The company plans to launch new products designed for enhancing home monitoring capabilities, targeting completion and release in the next 18 months.